JAN 19, 2019 08:30 PM PST

Therapeutic Avenues in Chronic Liver Disease

WRITTEN BY: Nouran Amin

Known as being a silent killer, diagnosing chronic liver disease in its early stages remains a clinical challenge because of no apparent symptoms until the disease has reached an advanced stage. However, a recent research study may be able to combat this clinical issue by providing a new diagnostic marker and therapeutic target for treatments strategies against chronic liver diseases.

Learn more about liver diseases:

Specifically, the researchers identified a novel pathway involved in the regulation of certain signaling pathways induced by extracellular matrix (ECM). The discovered that a certain protein-- endotrophin (ETP), a marker for collagen type VI (COL6) formation being the link between obesity and cancer—holds significance in creating a pathological microenvironment in the liver tissues of chronic liver disease.

"ETP levels in adipose tissues are elevated in obesity or diabetes and are associated with adipose tissue fibrosis, inflammation, and angiogenesis, leading to metabolic dysfunction in adipose tissues and systemic insulin resistance," says Professor Jiyoung Park in the School of Life Sciences at UNIST who first discovered ETP in 2012. "Through the identification of the correlation between ETP and chronic liver disease, this study opened new doors in the fight against liver diseases."

The researchers examined the liver tissues derived from patients with hepatocellular carcinoma (HCC) and found ETP in tumor-neighboring regions are implicated with poor prognosis of HCC patients. To observe the direct function of ETP in liver tissues, researchers generated an inducible, liver-specific ETP transgenic mouse (Alb-ETP) and found that ETP overexpression is related to liver cancer.

This is a schematic image showing the ETP expression and survival rate in liver tissue from HCC patients.

Credit: UNIST

"Therapeutic antibodies that inhibit the activity of ETP can be used to break the vicious circle that occurs between liver tissue cells," says Professor Park. "This suggests that ETP may be developed as a target substance for a specific therapeutic agent for treating patients with chronic liver disease. ETP is an extracellular substance that can be easily detected in blood. ETP, which appears in the early stage of chronic liver disease, may also serve as an early diagnostic marker."

Source: Ulsan National Institute of Science and Technology (UNIST)

About the Author
  • Nouran enjoys writing on various topics including science & medicine, global health, and conservation biology. She hopes through her writing she can make science more engaging and communicable to the general public.
You May Also Like
NOV 22, 2019
Drug Discovery & Development
NOV 22, 2019
Can FDA Approved Ketamine Drug Spravato Really Treat Depression?
President Trump is allegedly in support of a new drug to combat depression. He even urged the Department of Veterans Affairs to purchase it and “get ...
NOV 22, 2019
Genetics & Genomics
NOV 22, 2019
How Epigenetics Could Cure Addiction
Addictive behavior is characterized by relapse- being triggered by environmental factors to re-engage in harmful behavior from drug abuse to self harm. One...
NOV 22, 2019
Drug Discovery & Development
NOV 22, 2019
AI Exponentially Accelerates Drug Development
Research and development for new drugs is both an expensive and lengthy process, often lasting years, if not decades. With the development of artificial in...
NOV 22, 2019
Drug Discovery & Development
NOV 22, 2019
Nanomesh Development Advances Drug Delivery's Fight Against Antibiotic-Resistance
As concern over medication-resistant bacteria grows, researchers at Flinders University have now fabricated nanomeshes as an effective drug delivery method...
NOV 22, 2019
Cancer
NOV 22, 2019
Using senolytics to treat cancer
New research published in Nature Metabolism proposes using an already existing drug – a cardiac glycoside called ouabain – as a senolytic to ki...
NOV 22, 2019
Drug Discovery & Development
NOV 22, 2019
FDA Approves New Drug for Sickle Cell Disease
Sickle cell disease affects approximately 100,000 Americans. Currently, the only available cure for the disease is a costly bone marrow transplant, putting...
Loading Comments...